The Japan patent office has issued a patent that protects the manufacturing processes for KAND567 and KAND145

2023-03-21

Kancera AB (publ) today reports that the Japan patent office has issued a patent that protects the manufacturing processes for Kancera’s Fractalkine blocking drug candidates KAND567 and KAND145.

Kancera today reports that the Japan patent office has issued a patent that protects the manufacturing processes for KAND567 and KAND145. The patent, JP7225379, is owned by Kancera and is valid until 2039. Kancera has previously reported that the US patent office has granted a similar patent in the US, US 11,542,281.

”It is encouraging that we are staying on track with our IP strategy and continuously strengthen the product protection of our Fractalkine program. We see significant market opportunities in Japan, especially for our cancer programs. Together with USA and Europe, Japan is a very important market for us, in our licensing and partnering discussions with pharmaceutical companies”, says Thomas Olin, CEO at Kancera.

This patent concerns Kancera’s two drug candidates KAND567 and KAND145. KAND567 is currently being studied in two clinical trials, the FRACTAL and KANDOVA studies. The FRACTAL-study is a phase IIa clinical study of KAND567 in myocardial infarction patients undergoing percutaneous coronary intervention. Patient recruitment has been completed and top line results are expected to be presented in Q3 2023.The KANDOVA-study is a combined phase Ib/IIa study of KAND567 in combination with carboplatin therapy in ovarian cancer patients with relapsed disease. Patient recruitment is planned to start in Q2 2023 and top line results are expected to be presented during the second half of 2024. KAND145 is Kancera’s second generation Fractalkine blocking drug candidate and a phase I First-In-Human study is planned to be conducted and reported during 2023.

About Kancera AB (publ)
Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases. Kancera’s main focus is to develop small molecule drug candidates based on the Fractalkine system. Fractalkine is a natural master regulator that with precision controls immune cells and cancer cells. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.

For further information:
Thomas Olin
Chief Executive Officer, Kancera AB
Tel: +46-73-620 40 01

Visit Kancera’s web page: https://www.kancera.com/en

Back